AbbVie shares sink after $21 bn deal for Pharmacyclics

AbbVie shares sank Thursday after the US pharmaceutical firm announced it will buy leukemia drug maker Pharmacyclics in a $21 billion deal.

AbbVie and Pharmacyclics said in a statement late Wednesday that their boards of directors had approved the acquisition, which strengthens AbbVie's cancer drugs pipeline.

The deal marks AbbVie's first major acquisition after it backed away from a planned takeover of Shire Pharmaceuticals that would have moved its tax base to Ireland after US authorities cracked down on tax inversions.

AbbVie will pay $261.25 per share in a mix of cash and AbbVie equity. That represents a 13.4 percent premium to Pharmacyclics closing price of $230.48 Wednesday.

AbbVie shares fell 2.2 percent to $58.94 in early trade Thursday, while Pharmacyclics jumped 10.6 percent to $254.97.

AbbVie said the acquisition will boost its already strong cancer treatment pipeline with Pharmacyclics's blockbuster drug Imbruvica that treats blood cancers.

The Chicago-based company, best known for the anti-inflammatory Humira, said that market was rapidly growing and near $24 billion globally.

"Significant opportunity exists with further Imbruvica indications, including solid tumors, the potential to leverage AbbVie's immunology expertise for the development of Pharmacyclics's immunology program, and advance AbbVie's efforts in ," it said.


Explore further

AbbVie to buy leukemia drugmaker Pharmacyclics for $21B

© 2015 AFP

Citation: AbbVie shares sink after $21 bn deal for Pharmacyclics (2015, March 5) retrieved 21 September 2019 from https://medicalxpress.com/news/2015-03-abbvie-bn-pharmacyclics.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
3 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more